Announcing Enjamb's backing by Y Combinator to build the agentic workspace for drug programs.Discovery and preclinical
Enjamb synthesizes target, disease, modality, and translational evidence, then helps draft the research plans, experiment rationale, and IND-enabling materials that move an asset forward.
Workspace prompt
Evaluate whether this target and indication package is ready to move into IND-enabling planning.
Agent response
Enjamb synthesizes translational evidence, highlights missing support, and drafts the decision materials needed by clinical and regulatory teams.
Execution runbook
Enjamb turns an open-ended program request into a reviewable chain of evidence, analysis, drafting, and audit.
Agents compare target biology, mechanism, disease context, biomarkers, and modality precedent.
The workspace pulls together preclinical studies, clinical analogs, safety signals, and internal findings.
Agents flag missing assays, unsupported claims, weak rationale, and unresolved patient-selection questions.
Outputs become a source-backed rationale, experiment plan, risk memo, and IND-supporting narrative draft.
Use case workflow
Evidence
Agents map the disease landscape, compare target and modality precedent, and surface the evidence that matters for go/no-go decisions.
IND readiness
The same evidence can flow into protocols, briefing materials, and IND-supporting narratives without reassembling context from scratch.
Agent team
Synthesizes disease, target, biomarker, and modality evidence.
Finds validated assays, protocols, reagents, and experimental precedents.
Connects preclinical evidence to patient selection and clinical hypotheses.
Shapes the evidence into reviewer-ready rationale and gap analysis.
Artifacts produced
Review safeguards
Outcomes
The goal is not more documents. It is a faster, more traceable way to move program work into review.
Faster target and indication diligence
Clearer preclinical-to-clinical rationale
Less context loss between discovery and development